ALUMNI & ADVANCEMENT CORNER
Prostate Cancer
Research Advanced
by Partnerships and
Collaboration
For many men, there are few things more frightening
than a prostate cancer diagnosis. Prostate cancer is the
third leading cause of death from cancer in men in
Canada. On average, 65 men are diagnosed every day,
from which 11 succumb to the disease.
With these statistics in mind, I am very pleased to
share that the Department of Surgery has partnered with
Astellas Pharma to create the Astellas Prostate Cancer
Innovation Fund, an unrestricted UofT research fund
with the purpose of supporting, advancing and catalyzing
prostate cancer research. Under the direction and
supervision of an interdisciplinary UofT review committee,
overseen by the Chair of the Division of Urology,
the fund will provide $150,000 in annual funding, for a
period of 3 years.
|
Given the interdisciplinary and collaborative nature
of research, the competition is open to faculty members
in the Faculty of Medicine and across UofT’s affiliated
hospitals and research institutes, with academic appointment
to any of the following Departments: Surgery,
Medicine, Laboratory Medicine & Pathobiology,
Radiation Oncology, and Medical Imaging.
Led by the Division of Urology, our Department of
Surgery is at the forefront of prostate cancer research,
striving to improve both patient outcomes and patient
care. Our researchers have earned an international reputation
for excellence in advancing the latest research into
innovative therapies for men with prostate cancer.
Astellas has been a long-time supporter of the
Department of Surgery and the Division of Urology, and
we’d like to extend our sincere thanks for their continued
leadership and support.
Darina Landa, Director of Development
University of Toronto, Faculty of Medicine
|